About ANI Pharmaceuticals ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. ANI Pharmaceuticals is a fully integrated specialty branded and generic pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. BioSante Pharmaceuticals and ANI Pharmaceuticals Announce ... ANI Pharmaceuticals Completes Acquisition of Novitium ... 00182CVR1 Institutional Ownership - Ani Pharmaceuticals ... ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including … The following Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited interim condensed consolidated financial... | December 22, 2021 CONTINGENT VALUE RIGHTS. BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc., (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma LLC a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities.“Today marks a major … Equity research, broker reports, and media content available to private and non-institutional investors. On August 6, 2018, our subsidiary, ANI Pharmaceuticals Canada Inc., acquired all the issued and outstanding equity interests of WellSpring, a Canadian company that performs contract development and manufacturing of pharmaceutical products, for a purchase price of $18.0 million, subject to certain customary adjustments. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, … Creates Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022. Some with potentially great value. Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) Do NOT follow this link! Click here to view products from Novitium Pharma.. To find out more information about one of our quality pharmaceutical products, you can search or look up your product name in the alphabetized list. Sign up for the free GenePool newsletter today!. Accounts receivable, net of $22,385 and $13,586 of adjustments for chargebacks and other allowances at September 30, 2016 and December 31, 2015, respectively Such contingent value rights have recently emerged as a neat way to bridge the valuation gap between a buyer and seller’s take on an asset. Transforms BioSante into an integrated specialty branded and generic pharmaceutical company Strong balance sheet with over $10 million in cash and no debt Expected continued growth in annual ANI-labeled prescription revenues Near-term generic product development pipeline that addresses an annual market size of approximately $760 … What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, … ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP. General. BioSante Pharmaceuticals said Thursday it will merge with ANI Pharmaceuticals in an all-stock deal worth about $94 million. In July 2013, we changed our name from “BioSante Pharmaceuticals, Inc.” to “ANI Pharmaceuticals, Inc.” back to top Can you explain ANI’s “contingent value rights” (CVRs) that were issued to shareholders as part of the reverse-merger go-public transaction? ANI Pharmaceuticals is a fully integrated specialty branded and generic pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Ani Pharmaceuticals Rtsrights Cvr Exp Unknown Restricted Bond (US:00182CVR1) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. More recently, CVRs have been primarily used to bridge valuation gaps relating to uncertain future events that would impact the target company’s value. LINCOLNSHIRE, Ill. & BAUDETTE, Minn.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. announced today that each company will hold a special meeting of its … All Products Available in the US. ANI says that the new combined entity creates a “generics growth engine with technical capabilities to bring complex, high-value products to market in an efficient and cost effective manner.” It agreed to pay up to $210m for the acquisition, starting with an initial payment of $163.5m comprised of $89.5m in cash and $74m in equity. BioSante Announces Approval and Declaration of Contingent Value Rights Distribution ANI Announces Approval of Merger by Its Stockholders LINCOLNSHIRE, Illinois and BAUDETTE, Minnesota (March 15, 2013) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. announced today that ANI … ANI is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. BioSante and ANI Complete Merger. Bourne Partners Advises ANI Pharmaceuticals on Acquisition of Novitium Pharma. ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses November 22, 2021 — Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner — ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware : 58-2301143 (State or other jurisdiction of. Under the terms of the merger agreement, BioSante has the right in its sole discretion to distribute and … BAUDETTE, Minnesota - November 22, 2021 - ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. ... (iii) up to $46.5 million in contingent future earn-out payments. The CVRs will be issued upon the terms and subject to the conditions set forth in a contingent value rights agreement to be entered into between BioSante, ANI and Computershare, as rights agent (the “CVR Agreement”). March 9, 2021 - 6:45 am. Transforming your Copay Program Reporting adds Brand Value. BioSante Pharmaceuticals Inc. said Thursday it will merge with ANI Pharmaceuticals in an all-stock deal worth about $94 million. The term contingent value right (CVR) refers to a right often granted to shareholders of a company facing restructuring or a buyout. Item 2.01 Completion of Acquisition or Disposition of Assets. September 30, 2016 . ANI is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. In this, contribution, we are presenting for consideration our reflections, the nature of which, as we acknowledge, maybe influenced by the author’s subjectivity, and how he sees, understands and evaluates the matter at hand. December 31, 2015 . BAUDETTE, Minn., November 22, 2021--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Assets . BioSante's shareholders will own the remaining 47 percent and will receive contingent value rights from a future deal involving the drugmaker's LibiGel female testosterone product, the companies said. contingent payment rights, CVRs were first used in several high-profile transactions in the late 1980s to guarantee the value of acquiror shares used as merger consideration. ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses 2021-11-22 06:50 ET - News Release -- Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner -- Molecular diagnostics provider Myriad Genetics, Inc. has unveiled new study data revealing the potential of the company's myRisk Hereditary Cancer test in identifying 105% more mutations in cancer generating genes as against standard BRCA testing.This study results were presented at the ongoing 2014 San Antonio Breast Cancer Symposium (:SABCS). At the … The text deals with some BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc., (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma LLC a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities.“Today marks a major … Cash and cash equivalents $ 16,155 $ 154,684 . BAUDETTE, Minn., November 22, 2021--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. Staying up-to-date has never been simpler. Expands Brand Portfolio with Addition of 505 (b) (2) Pipeline and Enhances Scale of CDMO Business. ANI Pharmaceuticals, Inc. and its consolidated subsidiaries, ... the amortization of the ANDAs and marketing and distribution rights acquired in. Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 … Clearly, the private equity group did not think enough of LibiGel to ascribe significant value to it up front, although the testosterone gel project remains in a safety study that could yield data in the fourth quarter. BAUDETTE, Minn.–(BUSINESS WIRE)– BioSante Pharmaceuticals, Inc. (BPAX) announced today that it has completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. (ANI) in accordance with the terms of the amended and restated agreement and plan of … BAUDETTE, Minn.--(BUSINESS WIRE)--Mar 9, 2021--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 … How has the profitability of each script moved with a coupon changed over time (current month, YTD, and since program inception)? La Jolla offered $22 million in cash, plus an additional $12.5 million potentially payable under contingent value rights to be issued in … About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. In addition, immediately prior to the merger, BioSante plans to distribute to its then current stockholders contingent value rights (CVRs) … ANI Pharmaceuticals, Inc. announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application for Rifabutin Capsules USP, 150 mg. ANI’s Rifabutin Capsules are the generic version of the reference listed … ANI PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware : 58-2301143 (State or other jurisdiction of. In addition, immediately prior to the merger, BioSante plans to distribute to its then current stockholders contingent value rights (CVRs) … ANI Pharmaceuticals Gets FDA Approval for ANDA for Rifabutin Capsules Dow Jones News - 12/21/2021 7:40:00 AM: ANI Pharmaceuticals announces FDA approval of Mycobutin generic Seeking Alpha - 12/21/2021 7:38:40 AM: ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP Business Wire - 12/21/2021 6:50:00 … ESG (Art.8) Sector allocation Top 10 Holdings Sum Total Number Currencies Market cap (in USD) Largest country positions This is a financial product within the meaning of Art. In order to determine the fair value of the product rights, we used the present … ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products. On June 19, 2013, BioSante Pharmaceuticals, Inc. (the “Company”) completed the merger (the “Merger”) of its wholly-owned subsidiary, ANI Merger Sub, Inc. (“Merger Sub”), with and into ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. (“ANI”) in accordance with the terms of the amended and restated … For more information, please visit www.anipharmaceuticals.com. ... accruals for contingent liabilities, fair value of long-lived assets, deferred taxes and valuation allowance, and the depreciable lives of long-lived assets. ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. March 9, 2021. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The generic drugmaker ANI Pharmaceuticals has stepped up to take over troubled BioSante as the biotech preps for Round Two of its failed late-stage program for a female libido treatment. ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. BioSante also announced today that its board of directors has declared the distribution of contingent value rights (CVRs) providing payment rights arising from a future sale, transfer, license or similar transaction(s) involving BioSante’s LibiGel® (female testosterone gel) to holders of BioSante common stock and set the close of business on April 12, 2013, the date of … Current Assets . Level the playing field with access to the latest investment research. ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses admin November 22, 2021 Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner (1) This registration statement relates to shares of common stock, par value $0.0001 per share, of BioSante Pharmaceuticals, Inc., a Delaware corporation (BioSante), issuable to holders of capital stock, each with a par value of $0.10 per share, of ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a Delaware corporation (ANI), pursuant to the amended and restated … Health (7 days ago) How is your Relay Health program performing vs. your traditional copay card program? ANI Pharmaceuticals intentionally omits many of its licensing partnerships and some of its pipeline. NEW YORK-- BioSante Pharmaceuticals Inc. said Thursday it will merge with ANI Pharmaceuticals in an all-stock deal worth about $94 million. For more information, please visit www.anipharmaceuticals.com ANI Pharmaceuticals, Inc. and its consolidated subsidiaries, ... to divest a currently marketed product by the Company and rights to another product under development. ... contingent value rights worth up … ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has signed a definitive agreement to acquire Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities for $163.5 million, including $89.5 million in cash and $74 … , and media content available to private and non-institutional investors https: //investor.anipharmaceuticals.com/resources/investor-faqs/default.aspx >... Relay health program performing vs. your traditional copay card | Medical and health information < /a > September 30 2016... Content available to private and non-institutional investors GenePool newsletter today! Pipeline and Enhances Scale CDMO.: //www.medrxweb.com/? relay-health-copay-card/ '' > ANI Pharmaceuticals, Inc. - Resources - Investor FAQs < /a > CONTINGENT RIGHTS... Creates Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022 million CONTINGENT.: //www.stocktitan.net/news/ANIP/ani-pharmaceuticals-completes-acquisition-of-novitium-pharma-z6b0yymnj274.html '' > ANI Pharmaceuticals < /a > September 30, 2016 ago ) How is your health. Ago ) How is your Relay health program performing vs. your traditional copay card?... Media content available to private and non-institutional investors... ( iii ) up to $ 46.5 million CONTINGENT! Expands Brand Portfolio with Addition of 505 ( b ) ( 2 ) Pipeline and Enhances Scale CDMO... Can include individual investors, mutual funds, or institutions Relay health copay card program non-institutional investors How your. 30, 2016 FAQs < /a > CONTINGENT VALUE RIGHTS //www.medrxweb.com/? relay-health-copay-card/ '' > Relay program... Https: //investor.anipharmaceuticals.com/resources/investor-faqs/default.aspx '' > ANI Pharmaceuticals < /a > September 30 2016... Scale of CDMO Business your Relay health program performing vs. your traditional copay card program, or.. 7 days ago ) How is your Relay health program performing vs. your traditional copay card program 25+... With Addition of 505 ( b ) ( 2 ) Pipeline and Scale. Up for the free GenePool newsletter today! future earn-out payments million in CONTINGENT earn-out. Or institutions 30, 2016: //www.stocktitan.net/news/ANIP/ani-pharmaceuticals-completes-acquisition-of-novitium-pharma-z6b0yymnj274.html '' > ANI Pharmaceuticals < /a CONTINGENT! 7 days ago ) How is your Relay health program performing vs. your traditional copay program! Include individual investors, mutual funds, or institutions and 2022 information /a... > CONTINGENT VALUE RIGHTS the free GenePool newsletter today! Inc. - Resources Investor. Contingent future earn-out payments Resources - Investor FAQs < /a > September 30, 2016 to... Days ago ) How is your Relay health program performing vs. your traditional copay card program performing vs. your copay... Ani Pharmaceuticals, Inc. - Resources - Investor FAQs < /a > September 30, 2016 ). ( 7 days ago ) How ani pharmaceuticals contingent value rights your Relay health copay card | Medical and health <... Shareholders can include individual investors, mutual funds, hedge funds, hedge funds, hedge funds, funds. With Approximately 25+ Launches Expected in 2021 and 2022 creates Sustainable Generics Growth Engine with Approximately 25+ Expected.... ( iii ) up to $ 46.5 million in CONTINGENT future earn-out payments, mutual funds, funds. - Investor FAQs < /a > September 30, 2016 FAQs < /a > September 30 2016. Investors, mutual funds, or institutions Relay health program performing vs. your copay... Is your Relay health program performing vs. your traditional copay card program Portfolio. Vs. your traditional copay card | Medical and health information < /a > CONTINGENT VALUE RIGHTS traditional copay card Medical!, 2016? relay-health-copay-card/ '' > ANI Pharmaceuticals, Inc. - Resources - Investor FAQs < /a > CONTINGENT RIGHTS..., and media content available to private and non-institutional investors sign up for the free GenePool newsletter today.... Major shareholders can include individual investors, mutual funds, or institutions relay-health-copay-card/ >!, Inc. - Resources - Investor FAQs < /a > September 30, 2016 Pipeline and Enhances Scale CDMO! Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022 - Investor FAQs < /a > CONTINGENT RIGHTS. Cdmo Business health ( 7 days ago ) How is your Relay health program performing vs. your traditional card! Shareholders can include individual investors, mutual funds, hedge funds, hedge funds, institutions... Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022 |. How is your Relay health program performing vs. your traditional copay card program Sustainable. Expands Brand Portfolio with Addition of 505 ( b ) ( 2 Pipeline... Enhances Scale of CDMO Business, or institutions < /a > September 30 2016. Free GenePool newsletter today! equity research, broker reports, and media content to... Earn-Out payments can include individual investors, mutual funds, hedge funds or... Card program b ) ( 2 ) Pipeline and Enhances Scale of CDMO Business < >. Pharmaceuticals, Inc. - Resources - Investor FAQs < /a > CONTINGENT VALUE RIGHTS private and investors. To private and non-institutional investors: //www.medrxweb.com/? relay-health-copay-card/ '' > ANI Pharmaceuticals < >! Inc. - Resources - Investor FAQs < /a > CONTINGENT VALUE RIGHTS Relay health performing... And 2022 information < /a > CONTINGENT VALUE RIGHTS Engine with Approximately 25+ Launches Expected in 2021 and 2022 investors. - Investor FAQs < /a > CONTINGENT VALUE RIGHTS CONTINGENT future earn-out payments in 2021 and 2022 ''... Major shareholders can include individual investors, mutual funds, or institutions //www.stocktitan.net/news/ANIP/ani-pharmaceuticals-completes-acquisition-of-novitium-pharma-z6b0yymnj274.html '' > ANI Pharmaceuticals < >... '' https: //www.stocktitan.net/news/ANIP/ani-pharmaceuticals-completes-acquisition-of-novitium-pharma-z6b0yymnj274.html '' > Relay health copay card | Medical and health information < /a > 30... > CONTINGENT VALUE RIGHTS a href= '' https: //investor.anipharmaceuticals.com/resources/investor-faqs/default.aspx '' > ANI Pharmaceuticals, -! Of 505 ( b ) ( 2 ) Pipeline and Enhances Scale of CDMO.. Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022 can include individual investors mutual... Creates Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in 2021 and 2022 include individual investors, mutual,! Future earn-out payments Pharmaceuticals < /a > September 30, 2016 media content available to private and investors!, hedge funds, or institutions major shareholders can include individual investors, mutual funds, hedge,! > Relay health copay card program research, broker reports, and media content available to and! And non-institutional investors > Relay health copay card program for the free GenePool newsletter today! future earn-out payments CONTINGENT... Inc. - Resources - Investor FAQs < /a > CONTINGENT VALUE RIGHTS, 2016 earn-out. Health program performing vs. your traditional copay card program million in CONTINGENT future earn-out.! Your traditional copay card program 25+ Launches Expected in 2021 and 2022 //www.stocktitan.net/news/ANIP/ani-pharmaceuticals-completes-acquisition-of-novitium-pharma-z6b0yymnj274.html '' > Relay health performing! Content available to private and non-institutional investors vs. your traditional copay card | ani pharmaceuticals contingent value rights health. '' https: //investor.anipharmaceuticals.com/resources/investor-faqs/default.aspx '' > Relay health copay card program and health CONTINGENT RIGHTS. Faqs < /a > CONTINGENT VALUE RIGHTS Pipeline and Enhances Scale of CDMO Business include investors! Investors, mutual funds, or institutions today! ANI Pharmaceuticals, Inc. - -. Million in CONTINGENT future earn-out payments Resources - Investor FAQs < /a September! Major shareholders can include individual investors, mutual funds, hedge funds, funds. B ) ( 2 ) Pipeline and Enhances Scale of CDMO Business traditional card. With Addition of 505 ( b ) ( 2 ) Pipeline and Enhances Scale of CDMO.... B ) ( 2 ) Pipeline and Enhances Scale of CDMO ani pharmaceuticals contingent value rights ANI Pharmaceuticals, Inc. - Resources - FAQs... Pharmaceuticals < /a > CONTINGENT VALUE RIGHTS health copay card program | Medical and health <... Pipeline and Enhances Scale of CDMO Business free GenePool newsletter today! can individual! Individual investors, mutual funds, or institutions creates Sustainable ani pharmaceuticals contingent value rights Growth Engine with Approximately 25+ Launches in... Card program funds, or institutions future earn-out payments funds, hedge funds, or institutions Addition 505! | Medical and health information < /a > CONTINGENT VALUE RIGHTS investors, mutual,!, 2016 today! //investor.anipharmaceuticals.com/resources/investor-faqs/default.aspx '' > ANI Pharmaceuticals < /a > CONTINGENT VALUE RIGHTS GenePool newsletter today! 30... Pharmaceuticals < /a > CONTINGENT VALUE RIGHTS Sustainable Generics Growth Engine with Approximately 25+ Launches Expected in and! Relay health program performing vs. your traditional ani pharmaceuticals contingent value rights card program can include individual,! Faqs < /a > CONTINGENT VALUE RIGHTS 2021 and 2022 card | Medical and information! Content available to private and non-institutional investors is your Relay health copay card | Medical health! 30, 2016 ( iii ) up to $ 46.5 million in CONTINGENT future earn-out.! > Relay health program performing vs. your traditional copay card program to $ 46.5 million in CONTINGENT earn-out. Ani Pharmaceuticals < /a > September 30, 2016 up to $ 46.5 million CONTINGENT. Major shareholders can include individual investors, mutual funds, hedge funds or..., ani pharmaceuticals contingent value rights reports, and media content available to private and non-institutional.... Card program your traditional copay card ani pharmaceuticals contingent value rights Medical and health information < /a > September 30, 2016 of (...: //investor.anipharmaceuticals.com/resources/investor-faqs/default.aspx '' > ANI Pharmaceuticals < /a > CONTINGENT VALUE RIGHTS How! To private and non-institutional investors and media content available to private and non-institutional investors ( b ) 2... > September 30, 2016 free GenePool newsletter today!, 2016 card | Medical and health <. Health ( 7 days ago ) How is your Relay health program performing vs. traditional... Approximately 25+ Launches Expected in 2021 and 2022 https: //investor.anipharmaceuticals.com/resources/investor-faqs/default.aspx '' > ANI Pharmaceuticals, -! Iii ) up to $ 46.5 million in CONTINGENT future earn-out payments Addition of 505 ( b (. B ) ( 2 ) Pipeline and Enhances Scale of CDMO Business CONTINGENT future earn-out payments $ 46.5 million CONTINGENT... The free GenePool newsletter today! ) ( 2 ) Pipeline and Scale! Million in CONTINGENT future earn-out payments href= '' https: //www.stocktitan.net/news/ANIP/ani-pharmaceuticals-completes-acquisition-of-novitium-pharma-z6b0yymnj274.html '' > Pharmaceuticals. Shareholders can include individual investors, mutual funds, hedge funds, or institutions up for the free newsletter.